본문 바로가기

A new flavonoid from Stellera chamaejasme L., stechamone, alleviated 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in a murine model

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q2
저널
INTERNATIONAL IMMUNOPHARMACOLOGY59 · pp.113 · 2018
피인용
Web of Science 26Scopus 28
FWCI (Scopus)
0.92
JCR IF
JCR 2017 3.118
ISSN
1567-5769

저자

  1. 조범근제1저자College of Pharmacy, Pusan National University, Busan, South Korea
  2. Park, No-JuneNatural Products Research Institute, Korea Institute of Science and Technology, Gangneung, South Korea
  3. 제갈종환College of Pharmacy, Pusan National University, Busan, South Korea
  4. Choi, SanghoInternational Biological Material Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea
  5. Lee, Sang WooInternational Biological Material Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea
  6. Jin, HangInstitute of Medicinal Plants, Yunnan Academy of Agricultural Sciences, China
  7. Kim, Su-Nam교신저자College of Pharmacy, Pusan National University, Busan, South Korea
  8. 양민혜Natural Products Research Institute, Korea Institute of Science and Technology, Gangneung, South Korea

초록

Stellera chamaejasme L. (family Thymelaeaceae), also known as 'Langdu', has been traditionally used to treat of skin-related diseases, such as, psoriasis and skin ulcers. The aim of this study was to identify the biologically active component of S. chtunaejasme and evaluate its preventive effects on IL-4 and mast cell degranulation in RBL-2H3 cells and on the development of atopic dermatitis (AD) in 2,4-dinitrochlorobenzene (DNCB)-treated SKH-1 hairless mice. A novel flavonoid, genkwanin 5-O-xylosykl(1 -> 2))glucoside (named stechamone), and three known compounds (umbelliferone, luteolin, and luteolin-7-O-glucoside) were isolated from the aerial parts of S. chamaejasme using chromatographic methods. Of these four compounds, stechamone most potently inhibited IL-4 production and mast cell degranulation in RBL-2H3 cells. Topical application of 0.5% stechamone improved atopic skin symptoms, including, erythema (redness), pruritus (itching), exudation (weeping), excoriation (peeling), and licheniflcation (skin thickening) in DNCB-treated AD mice by accelerating skin barrier recovery function and suppressing inflammatory cell infiltration. In addition, stechamone attenuated DNCB-induced increases in IL-4 (an inflammatory T(H)2 cytokine) expression and in serum IgE levels in our murine model of AD. DNCB induced AD-like skin lesions, but treatment with stechamone exhibited strong anti-atopic activity by regulating skin barrier function and reducing inflammatory responses. The results obtained suggest stechamone is a potential anti-atopic agent and treatment for skin inflammatory diseases.

키워드

Stellera chamaejasme L.StechamoneAtopic dermatitis2,4-DinitrochlorobenzeneSkin barrier functionInterleukin 4IMMUNE DYSREGULATIONBARRIERANTIOXIDANTSPIMECROLIMUSDISEASESHEALTHDRUG

식별자

Scopus EID
2-s2.0-85045065808
WoS UID
000434004500014